HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Celldex Therapeutics, maintaining a price target of $80. Analyst Joseph Pantginis continues to support the stock, indicating confidence in its potential growth.
September 26, 2024 | 10:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Celldex Therapeutics, maintaining a price target of $80. Analyst Joseph Pantginis continues to support the stock, indicating confidence in its potential growth.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term. The analyst's confidence suggests strong potential for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100